We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.6M
AUM Growth
-$6.96M
Cap. Flow
-$10.5M
Cap. Flow %
-10.84%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$5.41M
2
KURA icon
Kura Oncology
KURA
+$4.15M
3
BLPH
Bellerophon Therapeutics, Inc.
BLPH
+$631K
4
AKAO
Achaogen Inc
AKAO
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RUBY
1
DELISTED
Rubius Therapeutics, Inc
RUBY
$41.2M 42.64%
2,618,351
– –
KURA icon
2
Kura Oncology
KURA
$916M
$26.7M 27.65%
1,356,307
-250,000
-16% -$4.15M
FATE icon
3
Fate Therapeutics
FATE
$290M
$19.8M 20.45%
973,190
-300,000
-24% -$5.41M
CHMA
4
DELISTED
Chiasma, Inc. Common Stock
CHMA
$8.94M 9.26%
1,196,776
– –
BLPH
5
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-64,377
Closed -$631K
AKAO
6
DELISTED
Achaogen Inc
AKAO
– –
-624,544
Closed -$285K

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q2 2019 Portfolio in Review

As of Q2 2019, Arch Venture Management held 6 positions worth $96.6M, down 6.7% from $104M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $10.5M in Q2 2019, closing 2 positions and reducing 2 holdings. Its most notable exit was Bellerophon Therapeutics, Inc., an estimated $631K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Arch Venture Management's biggest Q2 2019 reduction was Fate Therapeutics, cutting an estimated $5.41M.
  • Arch Venture Management fully exited Bellerophon Therapeutics, Inc. in Q2 2019, selling an estimated $631K.
  • Arch Venture Management's ten largest holdings make up 100% of its $96.6M portfolio in Q2 2019.
  • Arch Venture Management opened 0 new positions and closed 2 in Q2 2019.
  • Arch Venture Management's portfolio value fell 6.7% quarter-over-quarter to $96.6M.

Based on Arch Venture Management's 13F filing for Q2 2019, filed 9 Aug 2019.